Global pharma major Lupin Limited (Lupin) announced the launch of the United States Food and Drug Administration (FDA) approved bromfenac ophthalmic solution, 0.07%. Lupin is the exclusive first-to-file for this product and is eligible for 180-day exclusivity.
Bromfenac ophthalmic solution, 0.07% is the generic equivalent of Prolensa ophthalmic solution, 0.07%, of Bausch & Lomb Inc. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
